

CHAPTER ONE: INTRODUCTION.....	1
STUDY OBJECTIVES.....	1
REASONS FOR DOING THIS STUDY.....	1
INTENDED AUDIENCE.....	2
SCOPE OF THE STUDY.....	2
METHODOLOGY.....	2
INFORMATION SOURCES.....	2
BCC ONLINE SERVICES.....	3
ABOUT THE AUTHOR.....	3
RELATED BCC RESEARCH REPORTS.....	4
DISCLAIMER.....	4
 CHAPTER TWO: EXECUTIVE SUMMARY.....	 5
EXECUTIVE SUMMARY.....	5
<i>SUMMARY TABLE GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS BY REGION, THROUGH 2016 (\$ MILLIONS)</i>	6
<i>SUMMARY FIGURE GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS BY REGION, 2009-2016 (\$ MILLIONS)</i>	6
 CHAPTER THREE: OVERVIEW.....	 7
DEFINITIONS.....	7
NEED FOR THE DOSAGE FORMS.....	8
CLASSIFICATION OF DRUG DELIVERY ACCORDING TO ROUTE OF ADMINISTRATION.....	8
ORAL DRUG DELIVERY.....	9
Significant Features of Rapid Disintegrating Tablets.....	9
<i>TABLE 1 ADVANTAGES AND DISADVANTAGES OF ORAL DRUG DELIVERY</i>	10
INJECTABLE OR PARENTERAL DRUG DELIVERY.....	10
<i>TABLE 2 ADVANTAGES AND DISADVANTAGES OF PARENTERAL DRUG DELIVERY</i>	11
PULMONARY DRUG DELIVERY.....	11
<i>TABLE 3 ADVANTAGES AND DISADVANTAGES OF PULMONARY DRUG DELIVERY</i>	12
Metered Dose Inhalers.....	12
<i>TABLE 4 ADVANTAGES AND DISADVANTAGES OF METERED DOSE INHALERS</i>	13
Dry Powder Inhalers.....	13
TOPICAL DRUG DELIVERY.....	13
Transmucosal Drug Delivery.....	14
Nasal Drug Delivery.....	14
<i>TABLE 5 ADVANTAGES AND DISADVANTAGES OF NASAL DRUG DELIVERY</i>	15
Oral Mucosal Drug Delivery.....	16

<i>TABLE 6 ADVANTAGES AND DISADVANTAGES OF ORAL MUCOSAL DRUG DELIVERY</i>	16
<i>TABLE 6 (CONTINUED)</i>	17
Rectal Drug Delivery	17
<i>TABLE 7 ADVANTAGES AND DISADVANTAGES OF RECTAL DRUG DELIVERY</i>	18
Ocular Drug Delivery.....	18
<i>TABLE 8 ADVANTAGES AND DISADVANTAGES OF OCULAR DRUG DELIVERY</i>	19
Vaginal Drug Delivery	19
<i>TABLE 9 ADVANTAGES AND DISADVANTAGES OF VAGINAL DRUG DELIVERY</i>	20
Transdermal Drug Delivery	20
<i>TABLE 10 ADVANTAGES AND DISADVANTAGES OF TRANSDERMAL DRUG DELIVERY</i>	21
CLASSIFICATION OF DRUG DELIVERY BASED ON TECHNOLOGY	22
SUSTAINED RELEASE DRUG DELIVERY.....	22
<i>TABLE 11 ADVANTAGES AND DISADVANTAGES OF SUSTAINED RELEASE DRUG DELIVERY</i>	23
PRODRUGS.....	23
Advantages of Prodrugs	23
<i>TABLE 12 ADVANTAGES AND DISADVANTAGES OF PRODRUGS</i>	24
IMPLANTS AND IUDS	24
<i>TABLE 13 ADVANTAGES AND DISADVANTAGES OF IMPLANTS AND IUDS</i>	25
TARGETED DRUG DELIVERY.....	25
Ideal Characteristics of Targeted Drug Delivery	26
Nanoparticles	26
Liposomes.....	27
<i>TABLE 14 ADVANTAGES AND DISADVANTAGES OF LIPOSOMES</i>	28
Monoclonal Antibodies.....	28
<i>TABLE 15 ADVANTAGES AND DISADVANTAGES OF MONOCLONAL ANTIBODIES</i>	29
POLYMERIC DRUG DELIVERY.....	29
<i>TABLE 16 ADVANTAGES AND DISADVANTAGES OF POLYMERS</i>	30
PEGYLATION.....	31
<i>TABLE 17 ADVANTAGES AND DISADVANTAGES OF PEGYLATION</i>	31
REASONS AND EVOLUTION OF DRUG DELIVERY TECHNOLOGIES.....	32
<i>TABLE 18 EVOLUTION OF DRUG DELIVERY TECHNOLOGIES</i>	32
CLASSIFICATION BY APPLICATION	32
<i>TABLE 19 APPLICATIONS OF SUSTAINED RELEASE DOSAGE FORMS</i>	33

TABLE 19 (CONTINUED).....	34
TABLE 19 (CONTINUED).....	35
TABLE 19 (CONTINUED).....	36
TABLE 20 APPLICATIONS OF PRODRUGS.....	36
TABLE 20 CONTINUED).....	37
TABLE 21 APPLICATIONS OF TRANSDERMAL DRUG DELIVERY.....	37
TABLE 21 (CONTINUED).....	38
TABLE 22 APPLICATIONS OF IMPLANTS AND IUDS	39
TABLE 23 APPLICATIONS FOR PULMONARY DRUG DELIVERY.....	39
TABLE 23 (CONTINUED).....	40
TABLE 24 APPLICATIONS OF BUCCAL DRUG DELIVERY.....	40
TABLE 25 APPLICATIONS OF RECTAL DRUG DELIVERY	41
TABLE 26 APPLICATIONS OF OCULAR DRUG DELIVERY.....	41
TABLE 26 (CONTINUED).....	42
TABLE 27 APPLICATIONS OF VAGINAL DRUG DELIVERY	43
TABLE 28 APPLICATIONS OF LIPOSOMES.....	43
TABLE 29 APPLICATIONS OF NANOPARTICLES.....	44
TABLE 30 APPLICATIONS OF NANOPARTICLES.....	44
TABLE 30 (CONTINUED).....	45
TABLE 31 APPLICATIONS OF POLYMERS.....	45
TABLE 31 (CONTINUED).....	46
TABLE 32 APPLICATIONS OF PEGYLATION	46
CHAPTER FOUR: REGULATORY ASPECTS	47
TABLE 33 NEW APPROVALS OF VARIOUS ADVANCED DRUG DELIVERY SYSTEMS, 2008 TO JUNE 2011	47
TABLE 33 (CONTINUED).....	48
TABLE 33 (CONTINUED).....	49
TABLE 34 SAFETY ALERTS, JULY 2007 TO JUNE 2011	50
TABLE 34 (CONTINUED).....	51
CHAPTER FIVE: INDUSTRY STRUCTURE	52
MANUFACTURERS/ SUPPLIERS OF DRUG DELIVERY SYSTEMS	52
SUSTAINED RELEASE DOSAGE FORMS	52
TABLE 35 LEADING MANUFACTURERS/SUPPLIERS OF SUSTAINED RELEASE ORAL DOSAGE FORMS.....	52
TABLE 35 (CONTINUED).....	53
TABLE 36 LEADING MANUFACTURERS/SUPPLIERS OF SUSTAINED RELEASE INJECTABLE DOSAGE FORMS.....	54
TABLE 37 LEADING MANUFACTURERS/SUPPLIERS OF SUSTAINED RELEASE TOPICAL DOSAGE FORMS.....	55
PRODRUGS.....	55
TABLE 38 LEADING MANUFACTURERS/SUPPLIERS OF PRODRUGS	55
TABLE 38 (CONTINUED).....	56

<i>TABLE 39 LEADING MANUFACTURERS/SUPPLIERS OF IMPLANTS AND IUDS.....</i>	<i>56</i>
<i>TRANSDERMAL DRUG DELIVERY SYSTEMS.....</i>	<i>57</i>
<i>TABLE 40 LEADING MANUFACTURERS/SUPPLIERS OF TRANSDERMAL DRUG DELIVERY SYSTEMS.....</i>	<i>57</i>
<i>PULMONARY DRUG DELIVERY SYSTEMS.....</i>	<i>58</i>
<i>TABLE 41 LEADING MANUFACTURERS/SUPPLIERS OF PULMONARY DRUG DELIVERY SYSTEMS.....</i>	<i>58</i>
<i>BUCCAL DRUG DELIVERY SYSTEM.....</i>	<i>59</i>
<i>TABLE 42 LEADING MANUFACTURERS/SUPPLIERS OF BUCCAL DELIVERY SYSTEMS.....</i>	<i>59</i>
<i>RECTAL DRUG DELIVERY SYSTEM.....</i>	<i>59</i>
<i>TABLE 43 LEADING MANUFACTURERS/SUPPLIERS OF RECTAL DELIVERY SYSTEMS.....</i>	<i>59</i>
<i>OCULAR DRUG DELIVERY SYSTEM.....</i>	<i>60</i>
<i>TABLE 44 LEADING MANUFACTURERS/SUPPLIERS OF OCULAR DELIVERY SYSTEMS.....</i>	<i>60</i>
<i>TABLE 44 (CONTINUED).....</i>	<i>61</i>
<i>VAGINAL DRUG DELIVERY SYSTEMS.....</i>	<i>62</i>
<i>TABLE 45 LEADING MANUFACTURERS/SUPPLIERS OF VAGINAL DELIVERY SYSTEMS.....</i>	<i>62</i>
<i>TARGETED DRUG DELIVERY SYSTEMS.....</i>	<i>62</i>
<i>TABLE 46 LEADING MANUFACTURERS/SUPPLIERS OF LIPOSOMES.....</i>	<i>62</i>
<i>TABLE 47 LEADING MANUFACTURERS/SUPPLIERS OF NANOPARTICLES.....</i>	<i>63</i>
<i>TABLE 48 LEADING MANUFACTURERS / SUPPLIERS OF MONOCLONAL ANTIBODIES.....</i>	<i>63</i>
<i>TABLE 48 (CONTINUED).....</i>	<i>64</i>
<i>POLYMERIC DRUG DELIVERY.....</i>	<i>64</i>
<i>TABLE 49 LEADING MANUFACTURERS/SUPPLIERS OF POLYMERS.....</i>	<i>64</i>
<i>TABLE 49 (CONTINUED).....</i>	<i>65</i>
<i>TABLE 50 LEADING MANUFACTURERS/SUPPLIERS OF PEGYLATED PRODUCTS.....</i>	<i>65</i>
<i>MARKET SHARES OF INDUSTRY LEADERS OF DRUG DELIVERY SYSTEMS.....</i>	<i>66</i>
<i>SUSTAINED RELEASE ORAL DOSAGE FORMS.....</i>	<i>66</i>
<i>TABLE 51 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF SUSTAINED RELEASE ORAL DOSAGE FORMS, 2010 (%).....</i>	<i>66</i>
<i>FIGURE 1 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF SUSTAINED RELEASE ORAL DOSAGE FORMS, 2010 (%).....</i>	<i>67</i>

SUSTAINED RELEASE INJECTABLE DOSAGE FORMS	67
<i>TABLE 52 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF SUSTAINED RELEASE INJECTABLE DOSAGE FORMS, 2010 (%).....</i>	<i>68</i>
<i>FIGURE 2 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF SUSTAINED RELEASE INJECTABLE DOSAGE FORMS, 2010 (%).....</i>	<i>68</i>
SUSTAINED RELEASE TOPICAL DOSAGE FORMS	69
<i>TABLE 53 GLOBAL MARKET SHARES OF MANUFACTURERS/ SUPPLIERS OF SUSTAINED RELEASE INJECTABLE DOSAGE FORMS, 2010 (%).....</i>	<i>69</i>
<i>FIGURE 3 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF SUSTAINED RELEASE TOPICAL DOSAGE FORMS, 2010 (%).....</i>	<i>70</i>
PRODRUGS.....	70
<i>TABLE 54 GLOBAL MARKET SHARES OF MANUFACTURERS/ SUPPLIERS OF PRODRUGS, 2010 (%).....</i>	<i>71</i>
<i>FIGURE 4 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF PRODRUGS, 2010 (%).....</i>	<i>71</i>
IMPLANTS AND IUDS	72
<i>TABLE 55 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF IMPLANTS AND IUDS, 2010 (%).....</i>	<i>72</i>
<i>FIGURE 5 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF IMPLANTS AND IUDS, 2010 (%).....</i>	<i>73</i>
PULMONARY DRUG DELIVERY SYSTEMS	73
<i>TABLE 56 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF PULMONARY DRUG DELIVERY SYSTEMS, 2010 (%).....</i>	<i>74</i>
<i>FIGURE 6 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF PULMONARY DRUG DELIVERY SYSTEMS, 2010 (%).....</i>	<i>74</i>
TRANSDERMAL DRUG DELIVERY SYSTEMS.....	75
<i>TABLE 57 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF TRANSDERMAL DRUG DELIVERY SYSTEMS, 2010 (%).....</i>	<i>75</i>
<i>FIGURE 7 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF TRANSDERMAL DRUG DELIVERY SYSTEMS, 2010 (%).....</i>	<i>76</i>
BUCCAL DRUG DELIVERY SYSTEMS	76
<i>TABLE 58 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF BUCCAL DRUG DELIVERY SYSTEMS, 2010 (%).....</i>	<i>76</i>

<i>FIGURE 8 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF BUCCAL DRUG DELIVERY SYSTEMS, 2010 (%)</i>	77
<i>RECTAL DRUG DELIVERY SYSTEMS</i>	77
<i>TABLE 59 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF RECTAL DRUG DELIVERY SYSTEMS, 2010 (%)</i>	77
<i>FIGURE 9 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF RECTAL DRUG DELIVERY SYSTEMS, 2010 (%)</i>	78
<i>OCULAR DRUG DELIVERY SYSTEMS</i>	78
<i>TABLE 60 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF OCULAR DRUG DELIVERY SYSTEM, 2010 (%)</i>	79
<i>FIGURE 10 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF OCULAR DRUG DELIVERY SYSTEMS, 2010 (%)</i>	79
<i>VAGINAL DRUG DELIVERY SYSTEMS</i>	80
<i>TABLE 61 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF VAGINAL DRUG DELIVERY SYSTEM, 2010 (%)</i>	80
<i>FIGURE 11 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF VAGINAL DRUG DELIVERY SYSTEMS, 2010 (%)</i>	81
<i>LIPOSOMES</i>	81
<i>TABLE 62 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF LIPOSOMES, 2010 (%)</i>	82
<i>FIGURE 12 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF LIPOSOMES, 2010 (%)</i>	82
<i>NANOPARTICLES</i>	83
<i>TABLE 63 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF NANOPARTICLES, 2010 (%)</i>	83
<i>FIGURE 13 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF NANOPARTICLES, 2010 (%)</i>	84
<i>MONOCLONAL ANTIBODIES</i>	84
<i>TABLE 64 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF MONOCLONAL ANTIBODIES, 2010 (%)</i>	85
<i>FIGURE 14 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF MONOCLONAL ANTIBODIES, 2010 (%)</i>	85
<i>POLYMERS</i>	86
<i>TABLE 65 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF POLYMERS, 2010 (%)</i>	86

<i>FIGURE 15 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF POLYMERS, 2010 (%).....</i>	87
PEGNOLOGY.....	87
<i>TABLE 66 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF PEGNOLOGY, 2010 (%).....</i>	88
<i>FIGURE 16 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF PEGNOLOGY, 2010 (%).....</i>	88
CHAPTER SIX: NEW DEVELOPMENTS	89
<i>TABLE 67 NEW DEVELOPMENTS IN SUSTAINED RELEASE ORAL DOSAGE FORMS</i>	89
<i>TABLE 68 NEW DEVELOPMENTS IN SUSTAINED RELEASE INJECTABLE DOSAGE FORMS.....</i>	90
<i>TABLE 69 NEW DEVELOPMENTS IN TOPICAL ORAL DOSAGE FORMS.....</i>	90
<i>TABLE 70 NEW DEVELOPMENTS IN IMPLANTS AND IUDS.....</i>	91
<i>TABLE 71 NEW DEVELOPMENTS IN TRANSDERMAL DRUG DELIVERY SYSTEMS.....</i>	92
<i>TABLE 72 NEW DEVELOPMENTS IN LIPOSOMAL DRUG DELIVERY.....</i>	92
<i>TABLE 73 NEW DEVELOPMENTS IN PEGYLATED DRUG DELIVERY.....</i>	93
<i>TABLE 74 NEW DEVELOPMENTS IN NANOPARTICLE DRUG DELIVERY.....</i>	93
<i>TABLE 74 (CONTINUED).....</i>	94
<i>TABLE 75 NEW DEVELOPMENTS IN BUCCAL DRUG DELIVERY.....</i>	94
<i>TABLE 76 NEW DEVELOPMENTS IN VAGINAL DRUG DELIVERY.....</i>	94
<i>TABLE 77 NEW DEVELOPMENTS IN RECTAL DRUG DELIVERY.....</i>	95
<i>TABLE 78 NEW DEVELOPMENTS IN INHALATION DRUG DELIVERY.....</i>	95
<i>TABLE 78 (CONTINUED).....</i>	96
<i>TABLE 78 (CONTINUED).....</i>	97
<i>TABLE 79 NEW DEVELOPMENTS IN PRODRUGS</i>	97
<i>TABLE 79 (CONTINUED).....</i>	98
<i>TABLE 80 NEW DEVELOPMENTS IN MONOCLONAL ANTIBODIES</i>	98
<i>TABLE 80 (CONTINUED).....</i>	99
<i>TABLE 80 (CONTINUED).....</i>	100
<i>TABLE 80 (CONTINUED).....</i>	101
<i>TABLE 80 (CONTINUED).....</i>	102
<i>TABLE 80 (CONTINUED).....</i>	103
<i>TABLE 80 (CONTINUED).....</i>	104
<i>TABLE 80 (CONTINUED).....</i>	105
CHAPTER SEVEN: MARKET ANALYSIS	106
MARKET ANALYSIS	106
MARKET REVENUE	107
<i>TABLE 81 GLOBAL MARKET FOR ADVANCED DRUG DELIVERY SYSTEM, THROUGH 2016 (\$ MILLIONS).....</i>	107

<i>FIGURE 17 GLOBAL MARKET FOR ADVANCED DRUG DELIVERY SYSTEM, 2009-2016 (\$ MILLIONS)</i>	108
SUSTAINED RELEASE DOSAGE FORMS	108
Oral Delivery Systems.....	108
Market Overview	109
Market Revenue.....	110
<i>TABLE 82 GLOBAL MARKET FOR SUSTAINED RELEASE ORAL DOSAGE FORMS BY REGION, THROUGH 2016 (\$ MILLIONS)</i>	110
<i>FIGURE 18 GLOBAL MARKET FOR SUSTAINED RELEASE ORAL DOSAGE FORMS BY REGION, 2009-2016 (\$ MILLIONS)</i>	111
INJECTABLES	111
Market Overview	112
Market Overview (Continued).....	113
Market Revenue	114
<i>TABLE 83 GLOBAL MARKET FOR SUSTAINED RELEASE INJECTABLE DOSAGE FORMS BY REGION, THROUGH 2016 (\$ MILLIONS)</i>	114
<i>FIGURE 19 GLOBAL MARKET FOR SUSTAINED RELEASE INJECTABLE DOSAGE FORMS BY REGION, 2009-2016 (\$ MILLIONS)</i>	115
TOPICAL	115
Market Overview	116
Market Revenue	117
<i>TABLE 84 GLOBAL MARKET FOR SUSTAINED RELEASE TOPICAL DOSAGE FORMS BY REGION, THROUGH 2016 (\$ MILLIONS)</i>	117
<i>FIGURE 20 GLOBAL MARKET FOR SUSTAINED RELEASE TOPICAL DOSAGE FORMS BY REGION, THROUGH 2016 (\$ MILLIONS)</i>	118
PRODRUGS.....	118
Market Overview	119
Market Revenue	120
<i>TABLE 85 GLOBAL MARKET FOR PRODRUGS BY REGION, THROUGH 2016 (\$ MILLIONS)</i>	120
<i>FIGURE 21 GLOBAL MARKET FOR PRODRUGS BY REGION, 2009-2016 (\$ MILLIONS)</i>	120
TRANSDERMAL DRUG DELIVERY	121
Market Overview	122
Market Revenue	123
<i>TABLE 86 GLOBAL MARKET FOR TRANSDERMAL DRUG DELIVERY SYSTEMS BY REGION, THROUGH 2016 (\$ MILLIONS)</i>	124
<i>FIGURE 22 GLOBAL MARKET FOR TRANSDERMAL DRUG DELIVERY SYSTEMS BY REGION, 2009-2016 (\$ MILLIONS)</i>	124
IMPLANTS AND IUDS	124
Market Overview	125
Market Overview (Continued).....	126

Market Revenue	127
<i>TABLE 87 GLOBAL MARKET FOR IMPLANTS AND IUDS BY REGION, THROUGH 2016 (\$ MILLIONS)</i>	127
<i>FIGURE 23 GLOBAL MARKET FOR IMPLANTS AND IUDS BY REGION, 2009-2016 (\$ MILLIONS)</i>	128
PULMONARY DRUG DELIVERY/INHALATION	128
Market Overview	128
Market Revenue	129
<i>TABLE 88 GLOBAL MARKET FOR PULMONARY DRUG DELIVERY SYSTEMS BY REGION, THROUGH 2016 (\$ MILLIONS)</i>	130
<i>FIGURE 24 GLOBAL MARKET FOR PULMONARY DRUG DELIVERY SYSTEMS BY REGION, 2009-2016 (\$ MILLIONS)</i>	130
BUCCAL DRUG DELIVERY.....	131
Market Overview	131
Market Revenue	132
<i>TABLE 89 GLOBAL MARKET FOR BUCCAL DRUG DELIVERY SYSTEMS BY REGION, THROUGH 2016 (\$ MILLIONS)</i>	132
<i>FIGURE 25 GLOBAL MARKET FOR BUCCAL DRUG DELIVERY SYSTEMS BY REGION, 2009-2016 (\$ MILLIONS)</i>	133
RECTAL DRUG DELIVERY	133
Market Overview	133
Market Revenue	134
<i>TABLE 90 GLOBAL MARKET FOR RECTAL DRUG DELIVERY SYSTEMS BY REGION, THROUGH 2016 (\$ MILLIONS)</i>	134
<i>FIGURE 26 GLOBAL MARKET FOR RECTAL DRUG DELIVERY SYSTEMS BY REGION, 2009-2016 (\$ MILLIONS)</i>	135
OCULAR DRUG DELIVERY	135
Market Overview	136
Market Revenue	137
<i>TABLE 91 GLOBAL MARKET FOR OCULAR DRUG DELIVERY SYSTEMS BY REGION, THROUGH 2016 (\$ MILLIONS)</i>	137
<i>FIGURE 27 GLOBAL MARKET FOR OCULAR DRUG DELIVERY SYSTEMS BY REGION, 2009-2016 (\$ MILLIONS)</i>	138
VAGINAL DRUG DELIVERY	138
Market Overview	139
Market Revenue	139
<i>TABLE 92 GLOBAL MARKET FOR VAGINAL DRUG DELIVERY SYSTEMS BY REGION, THROUGH 2016 (\$ MILLIONS)</i>	139
<i>FIGURE 28 GLOBAL MARKET FOR VAGINAL DRUG DELIVERY SYSTEMS BY REGION, 2009-2016 (\$ MILLIONS)</i>	140
TARGETED DRUG DELIVERY.....	140
Nanoparticles.....	140
Market Overview	141
Market Revenue.....	142

<i>TABLE 93 GLOBAL MARKET FOR NANOPARTICLES BY REGION, THROUGH 2016 (\$ MILLIONS)</i>	142
<i>FIGURE 29 GLOBAL MARKET FOR NANOPARTICLES BY REGION, 2009-2016 (\$ MILLIONS)</i>	143
Liposomes.....	143
Market Overview	144
Market Revenue.....	145
<i>TABLE 94 GLOBAL MARKET FOR LIPOSOMES BY REGION, THROUGH 2016 (\$ MILLIONS)</i>	146
<i>FIGURE 30 GLOBAL MARKET FOR LIPOSOMES BY REGION, 2009-2016 (\$ MILLIONS)</i>	146
Monoclonal Antibodies	146
Market Overview	147
Market Overview (Continued)	148
Market Revenue.....	149
<i>TABLE 95 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES BY REGION, THROUGH 2016 (\$ MILLIONS)</i>	149
<i>FIGURE 31 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES BY REGION, 2009-2016 (\$ MILLIONS)</i>	150
POLYMERIC DRUG DELIVERY.....	150
Market Overview	150
Market Overview (Continued).....	151
Market Revenue	152
<i>TABLE 96 GLOBAL MARKET FOR POLYMERS BY REGION, THROUGH 2016 (\$ MILLIONS)</i>	152
<i>FIGURE 32 GLOBAL MARKET FOR POLYMERS BY REGION, 2009-2016 (\$ MILLIONS)</i>	153
PEGYLATED PRODUCTS	153
Market Overview	153
Market Overview (Continued).....	154
Market Revenue	155
<i>TABLE 97 GLOBAL MARKET FOR PEGYLATED PRODUCTS BY REGION, THROUGH 2016 (\$ MILLIONS)</i>	155
<i>FIGURE 33 GLOBAL MARKET FOR PEGYLATED PRODUCTS BY REGION, 2009-2016 (\$ MILLIONS)</i>	156
MARKET SHARES OF DRUG DELIVERY DOSAGE FORMS, BY REGION	156
<i>TABLE 98 GLOBAL DRUG DELIVERY MARKET SHARES BY REGION, 2010 (%)</i>	156
<i>FIGURE 34 GLOBAL DRUG DELIVERY MARKET SHARES BY REGION, 2010 (%)</i>	157
CHAPTER EIGHT: MARKET BY END USERS.....	158
<i>TABLE 99 GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY APPLICATION, THROUGH 2016 (\$ MILLIONS)</i>	158

<i>FIGURE 35 GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY APPLICATION, 2009-2016 (\$ MILLIONS)</i>	159
CARDIOVASCULAR DISEASES	160
MARKET REVENUE.....	160
<i>TABLE 100 GLOBAL REVENUE FOR CARDIOVASCULAR DRUG DELIVERY SYSTEMS, THROUGH 2016 (\$ MILLIONS)</i>	161
<i>FIGURE 36 GLOBAL REVENUE FOR CARDIOVASCULAR DRUG DELIVERY SYSTEMS, 2009-2016 (\$ MILLIONS)</i>	161
Global Market Shares	162
<i>TABLE 101 GLOBAL MARKET SHARES OF CARDIOVASCULAR DRUG DELIVERY SYSTEMS BY REGION, 2010 (%)</i>	162
<i>FIGURE 37 GLOBAL MARKET SHARES OF CARDIOVASCULAR DRUG DELIVERY SYSTEMS BY REGION, 2010 (%)</i>	162
ONCOLOGY	163
MARKET REVENUE.....	163
<i>TABLE 102 GLOBAL REVENUE FOR ONCOLOGY DRUG DELIVERY SYSTEMS, THROUGH 2016 (\$ MILLIONS)</i>	164
<i>FIGURE 38 GLOBAL REVENUE FOR ONCOLOGY DRUG DELIVERY SYSTEMS, 2009-2016 (\$ MILLIONS)</i>	164
Global Market Shares	165
<i>TABLE 103 GLOBAL MARKET SHARES OF ONCOLOGY DRUG DELIVERY SYSTEMS BY REGION, 2010 (%)</i>	165
<i>FIGURE 39 GLOBAL MARKET SHARES OF ONCOLOGY DRUG DELIVERY SYSTEMS BY REGION, 2010 (%)</i>	165
GASTROINTESTINAL SYSTEMS	166
MARKET REVENUE.....	166
<i>TABLE 104 GLOBAL REVENUES FOR GASTROINTESTINAL DRUG DELIVERY SYSTEMS, THROUGH 2016 (\$ MILLIONS)</i>	167
<i>FIGURE 40 GLOBAL REVENUES FOR GASTROINTESTINAL DRUG DELIVERY SYSTEMS, 2009-2016 (\$ MILLIONS)</i>	167
Global Market Shares	168
<i>TABLE 105 GLOBAL MARKET SHARES OF GASTROINTESTINAL DRUG DELIVERY SYSTEMS BY REGION, 2010 (%)</i>	168
<i>FIGURE 41 GLOBAL MARKET SHARES OF GASTROINTESTINAL DRUG DELIVERY SYSTEMS BY REGION, 2010 (%)</i>	168
UROLOGY.....	169
MARKET REVENUE.....	169
<i>TABLE 106 GLOBAL REVENUE OF UROLOGY DRUG DELIVERY SYSTEMS, THROUGH 2016 (\$ MILLIONS)</i>	170
<i>FIGURE 42 GLOBAL REVENUE OF UROLOGY DRUG DELIVERY SYSTEMS, 2009-2016 (\$ MILLIONS)</i>	170
Global Market Share	171
<i>TABLE 107 GLOBAL MARKET SHARES OF UROLOGY DRUG DELIVERY SYSTEMS BY REGION, 2010 (%)</i>	171

<i>FIGURE 43 GLOBAL MARKET SHARES OF UROLOGY DRUG DELIVERY SYSTEMS BY REGION, 2010 (%).....</i>	<i>171</i>
DIABETES	172
MARKET REVENUE.....	172
<i>TABLE 108 GLOBAL REVENUE FOR DRUG DELIVERY SYSTEMS IN DIABETES, THROUGH 2016 (\$ MILLIONS).....</i>	<i>173</i>
<i>FIGURE 44 GLOBAL REVENUE FOR DRUG DELIVERY SYSTEMS IN DIABETES, 2009-2016 (\$ MILLIONS).....</i>	<i>173</i>
Global Market Shares	173
<i>TABLE 109 GLOBAL MARKET SHARES OF DRUG DELIVERY SYSTEMS IN DIABETES BY REGION, 2010 (%)</i>	<i>174</i>
<i>FIGURE 45 GLOBAL MARKET SHARES OF DRUG DELIVERY SYSTEMS IN DIABETES BY REGION, 2010 (%)</i>	<i>174</i>
CENTRAL NERVOUS SYSTEM	174
MARKET REVENUE.....	175
<i>TABLE 110 GLOBAL REVENUES FOR CENTRAL NERVOUS SYSTEM DRUG DELIVERY SYSTEMS, THROUGH 2016 (\$ MILLIONS).....</i>	<i>175</i>
<i>FIGURE 46 GLOBAL REVENUES FOR CENTRAL NERVOUS SYSTEM DRUG DELIVERY SYSTEMS, 2009-2016 (\$ MILLIONS)</i>	<i>176</i>
Global Market Shares	176
<i>TABLE 111 GLOBAL MARKET SHARES OF CENTRAL NERVOUS SYSTEM DRUG DELIVERY SYSTEMS BY REGION, 2010 (%).....</i>	<i>176</i>
<i>FIGURE 47 GLOBAL MARKET SHARES OF CENTRAL NERVOUS SYSTEM DRUG DELIVERY SYSTEMS BY REGION, 2010 (%).....</i>	<i>177</i>
RESPIRATORY DRUG DELIVERY SYSTEMS.....	177
MARKET REVENUE.....	177
<i>TABLE 112 GLOBAL REVENUE FOR RESPIRATORY DRUG DELIVERY SYSTEMS, THROUGH 2016 (\$ MILLIONS)</i>	<i>178</i>
<i>FIGURE 48 GLOBAL REVENUE FOR RESPIRATORY DRUG DELIVERY SYSTEMS, 2009-2016 (\$ MILLIONS).....</i>	<i>178</i>
Global Market Shares	179
<i>TABLE 113 GLOBAL MARKET SHARES OF RESPIRATORY DRUG DELIVERY SYSTEMS BY REGION, 2010 (%).....</i>	<i>179</i>
<i>FIGURE 49 GLOBAL MARKET SHARES OF RESPIRATORY DRUG DELIVERY SYSTEMS BY REGION, 2010 (%).....</i>	<i>179</i>
INFLAMMATORY DISEASES AND ALLERGIES.....	180
MARKET REVENUE.....	180
<i>TABLE 114 GLOBAL REVENUES FOR DRUG DELIVERY SYSTEMS FOR INFLAMMATORY DISEASES AND ALLERGIES, THROUGH 2016 (\$ MILLIONS).....</i>	<i>180</i>
<i>FIGURE 50 GLOBAL REVENUES FOR DRUG DELIVERY SYSTEMS FOR INFLAMMATORY DISEASES AND ALLERGIES, 2009-2016 (\$ MILLIONS).....</i>	<i>181</i>
Global Market Shares	181

<i>TABLE 115 GLOBAL MARKET SHARES OF DRUG DELIVERY SYSTEMS FOR INFLAMMATORY DISEASES AND ALLERGIES BY REGION, 2010 (%)</i>	181
<i>FIGURE 51 GLOBAL MARKET SHARES OF DRUG DELIVERY SYSTEMS FOR INFLAMMATORY DISEASES AND ALLERGIES BY REGION, 2010 (%)</i>	182
<i>OPHTHALMOLOGY</i>	182
<i>MARKET REVENUE</i>	182
<i>TABLE 116 GLOBAL REVENUE FOR DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY, THROUGH 2016 (\$ MILLIONS)</i>	183
<i>FIGURE 52 GLOBAL REVENUE FOR DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY, 2009-2016 (\$ MILLIONS)</i>	183
Global Market Shares	184
<i>TABLE 117 GLOBAL MARKET SHARE OF DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY BY REGION, 2010 (%)</i>	184
<i>FIGURE 53 GLOBAL MARKET SHARE OF DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY BY REGION, 2010 (%)</i>	184
<i>VIRAL AND BACTERIAL DISEASES</i>	185
<i>MARKET REVENUE</i>	185
<i>TABLE 118 GLOBAL REVENUE FOR DRUG DELIVERY SYSTEMS FOR VIRAL AND BACTERIAL DISEASES, THROUGH 2016 (\$ MILLIONS)</i>	185
<i>FIGURE 54 GLOBAL REVENUE FOR DRUG DELIVERY SYSTEMS FOR VIRAL AND BACTERIAL DISEASES, 2009-2016 (\$ MILLIONS)</i>	186
Global Market Shares	186
<i>TABLE 119 GLOBAL MARKET SHARES OF DRUG DELIVERY SYSTEMS FOR VIRAL AND BACTERIAL DISEASES BY REGION, 2010 (%)</i>	186
<i>FIGURE 55 GLOBAL MARKET SHARES OF DRUG DELIVERY SYSTEMS FOR VIRAL AND BACTERIAL DISEASES BY REGION, 2010 (%)</i>	187
<i>HORMONE REPLACEMENT THERAPY (HRT) AND GYNECOLOGY</i> ...	187
<i>MARKET REVENUE</i>	187
<i>TABLE 120 GLOBAL REVENUE FOR DRUG DELIVERY SYSTEMS FOR HORMONE REPLACEMENT THERAPY AND GYNECOLOGY, THROUGH 2016 (\$ MILLIONS)</i>	188
<i>FIGURE 56 GLOBAL REVENUE FOR DRUG DELIVERY SYSTEMS FOR HORMONE REPLACEMENT THERAPY AND GYNECOLOGY, 2009-2016 (\$ MILLIONS)</i>	188
Global Market Shares	189
<i>TABLE 121 GLOBAL MARKET SHARES OF DRUG DELIVERY SYSTEMS FOR HORMONE REPLACEMENT THERAPY AND GYNECOLOGY BY REGION, 2010 (%)</i>	189

<i>FIGURE 57 GLOBAL MARKET SHARES OF DRUG DELIVERY SYSTEMS HORMONE REPLACEMENT THERAPY AND GYNECOLOGY, 2010 (%)</i>	189
OTHERS.....	190
MARKET REVENUE.....	190
<i>TABLE 122 GLOBAL REVENUE FOR DRUG DELIVERY SYSTEMS FOR OTHER DISEASES, THROUGH 2016 (\$ MILLIONS)</i>	190
<i>FIGURE 58 GLOBAL REVENUE FOR DRUG DELIVERY SYSTEMS FOR OTHER DISEASES, 2009-2016 (\$ MILLIONS)</i>	191
Global Market Shares	191
<i>TABLE 123 GLOBAL MARKET SHARES OF DRUG DELIVERY SYSTEMS FOR OTHER DISEASES BY REGION, 2010 (%)</i>	191
<i>FIGURE 59 GLOBAL MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR OTHER DISEASES BY REGION, 2010 (%)</i>	192
TECHNOLOGIES	192
MARKET REVENUE.....	192
<i>TABLE 124 GLOBAL REVENUE FOR DRUG DELIVERY TECHNOLOGIES, THROUGH 2016 (\$ MILLIONS)</i>	193
<i>FIGURE 60 GLOBAL REVENUE FOR DRUG DELIVERY TECHNOLOGIES, 2009-2016 (\$ MILLIONS)</i>	193
Global Market Shares	193
<i>TABLE 125 GLOBAL MARKET SHARES OF DRUG DELIVERY TECHNOLOGIES BY REGION, 2010 (%)</i>	194
<i>FIGURE 61 GLOBAL MARKET SHARES OF DRUG DELIVERY TECHNOLOGIES BY REGION, 2010 (%)</i>	194
MARKET SHARE OF APPLICATIONS.....	195
<i>TABLE 126 SHARES OF DRUG DELIVERY SYSTEMS BY APPLICATIONS, 2010 (%)</i>	195
<i>FIGURE 62 SHARE OF DRUG DELIVERY SYSTEMS BY APPLICATIONS, 2010 (%)</i>	195
CHAPTER NINE: PATENT ANALYSIS	196
PATENTS BY YEAR.....	196
<i>TABLE 127 SIGNIFICANT PATENTS BY YEAR, 2007–2011 (NUMBER/%)</i>	197
<i>FIGURE 63 NUMBER OF PATENTS BY YEAR, 2007–2011</i>	197
<i>FIGURE 64 SIGNIFICANT OF PATENTS BY YEAR, 2007–2011 (%)</i>	198
PATENTS BY TYPE	198
<i>TABLE 128 PATENTS BY TYPE, 2007–2011</i>	199
<i>FIGURE 65 TOTAL PATENTS BY TYPE, 2007–2011 (%)</i>	199
<i>FIGURE 65 (CONTINUED)</i>	200
PATENTS BY COMPANY.....	200
<i>TABLE 129 NUMBER OF U.S. PATENTS BY COMPANY FOR DRUG DELIVERY SYSTEMS, 2007–2011</i>	201
<i>TABLE 129 (CONTINUED)</i>	202

<i>TABLE 129 (CONTINUED)</i>	203
PATENTS BY COUNTRY	203
<i>TABLE 130 TOTAL NUMBER OF U.S. PATENTS BY COUNTRY, 2007–</i>	
<i>2011</i>	204
PATENTS BY ASSIGNEE	204
<i>TABLE 131 PATENTS BY ASSIGNEE FOR DRUG DELIVERY</i>	
<i>SYSTEMS, 2007–2011</i>	205
<i>FIGURE 66 PATENTS BY ASSIGNEE FOR DRUG DELIVERY</i>	
<i>SYSTEMS, 2007–2011</i>	205
 CHAPTER TEN: CURRENT SITUATION, STRATEGIES, AND	
PROSPECTS.....	206
MARKET STATUS	206
FACTORS AFFECTING THE DRUG DELIVERY MARKET	206
PATENT EXPIRATION.....	206
<i>TABLE 132 BRANDS COMING OFF-PATENT, 2011–2012</i>	207
HURDLES IN LAUNCHING NEW CHEMICAL ENTITIES.....	207
INCREASING DEMAND OF PROTEIN THERAPEUTICS.....	208
DEVELOPMENT OF TARGETED DRUG DELIVERY	
CARRIERS	208
RISING NEED FOR TARGETED DRUG DELIVERY.....	208
BABY BOOMER GENERATION	208
POOR EFFICACY OF CERTAIN DRUGS.....	209
COMPETITION.....	209
INCREASED R&D AND GOVERNMENT FUNDING	209
COMPANY STRATEGIES	210
SETTLEMENTS BETWEEN BRAND AND GENERIC DRUG	
MANUFACTURERS.....	210
MERGER & ACQUISITIONS AND IN-LICENSING/ PARTNERSHIP	210
<i>TABLE 133 PRODUCTS OF NEKTAR VIA PARTNERSHIPS</i>	211
<i>TABLE 134 PRODUCTS OF ELAN DRUG TECHNOLOGIES IN</i>	
<i>PARTNERSHIP</i>	211
DEMANDS AND TRENDS	211
DEMANDS AND TRENDS (CONTINUED)	212
 CHAPTER ELEVEN: COMPANY PROFILES.....	213
ABBOTT LABORATORIES.....	213
AKELA PHARMA INC.	213
AKORN INC.....	214
ALCON INC.	214
ALEXION PHARMACEUTICALS	215
ALKERMES, INC.	215
ALLERGAN.....	216
ALPHARX	216

AMGEN	217
A.P. PHARMA	218
ASTELLAS PHARMA INC.....	218
ASTRAZENECA PLC	219
ATON PHARMA	219
BAXTER	220
BAYER HEALTHCARE PHARMACEUTICALS	221
BIOGEN IDEC	221
BIOSANTE PHARMACEUTICALS INC.....	222
BOEHRINGER INGELHEIM	222
BRISTOL MYERS SQUIBB	223
CELGENE CORPORATION 86 MORRIS AVENUE	223
CEPHALON INC.	224
COLUMBIA LABORATORIES INC.	225
EISAI CO.....	225
ELAN DRUG TECHNOLOGIES	226
ENZON PHARMACEUTICALS.....	226
EURAND N.V.....	227
GENENTECH	227
GENEREX BIOTECHNOLOGY CORPORATION.....	228
GENZYME	228
GILEAD SCIENCES, INC.....	229
GLAXOSMITHKLINE PLC	230
IMCLONE SYSTEMS.....	230
JANSSEN BIOTECH INC.....	231
JOHNSON & JOHNSON	231
KV PHARMACEUTICAL CO.....	232
LAVIPHARM CORPORATION.....	233
3M COMPANY	233
MERCK & CO.	234
MYLAN LABORATORIES INC.	235
NEKTAR THERAPEUTICS	235
NEUROGESX INC.....	236
NOVEN PHARMACEUTICALS, INC.....	237
NOVARTIS AG	237
NOVAVAX, INC.....	238
NYCOMED US INC.....	239
OSI PHARMACEUTICALS INC.....	239
PAR PHARMACEUTICAL COMPANIES, INC.	240
PDL BIOPHARMA INC.....	240
PFIZER INC.	241
QLT INC.....	241
ROCHE HOLDING AG	242
SANOFI SA	243

TEVA PHARMACEUTICAL INDUSTRIES LTD.	243
VALEANT PHARMACEUTICALS INTERNATIONAL	244
WATSON PHARMACEUTICALS, INC.	245
APPENDIX I—ABBREVIATIONS/DEFINITIONS	246
ABBREVIATIONS/DEFINITIONS	246
ABBREVIATIONS/DEFINITIONS (CONTINUED)	247